Yarrowia

AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819

Retrieved on: 
Tuesday, August 17, 2021
Company, Standard of care, U.S. Securities and Exchange Commission, Technology, Yarrowia, GLOBE, International, INN, World Health Organization, Cystic fibrosis, Pharmacist, World, Exocrine pancreatic insufficiency, Nutrient, International nonproprietary name, Clinical trial, Niclosamide, NASDAQ, WHO, Cystic Fibrosis Foundation, Patient, PERT, Diarrhea, CEO, EPI, Biopharma LLC, Steatorrhea, BOCA, Weight loss, COVID-19, Security (finance), Pharmaceutical industry

The assignment of adrulipase alfa as the proposed International Nonproprietary Name for MS1819 is an important step in the ongoing development of this drug technology, said James Sapirstein, President and CEO of AzurRx.

Key Points: 
  • The assignment of adrulipase alfa as the proposed International Nonproprietary Name for MS1819 is an important step in the ongoing development of this drug technology, said James Sapirstein, President and CEO of AzurRx.
  • AzurRx is pursuing parallel monotherapy and combination therapy clinical pathways with MS1819.
  • The WHO is expected to render a final decision on the use of adrulipase alfa for MS1819 by November 2021.
  • AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Biomedican Receives Approval Notification From the U.S. Patent Office on Its 1st Patent

Retrieved on: 
Tuesday, July 27, 2021
Drugs, Euphoriants, Cannabinoid, Psychoactive drugs, Appetite stimulants, Entheogens, Yarrowia, Tetrahydrocannabinol, Patent, Branches of biology

SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.

Key Points: 
  • SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Biomedican has received notification from the U.S. patent office that its first patent has been approved and will be issued in the coming months.
  • This is the first patent ever to be issued using Yarrowia Lipolytica to produce cannabinoids.
  • Enzymes which are converting CBGA into CBDA, CBCA and THCA are required for the presence of interaction of two phases: oil and water.
  • "Patenting the use of Yarrowia Lipolytica to produce cannabinoids gives Biomedican a significant competitive advantage in the biosynthesized cannabinoid market.